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Abstract 
Background 
The timings of efficacy-related clinical events recorded at scheduled study visits in clinical trials are interval-
censored with interval duration pre-determined by study protocol. Events may happen anytime during that interval 
but can only be detected during a planned or unplanned visit.  Disease progression in oncology is a notable example 
where time-to-event is affected by the schedule of visits within a study.  This can become a source of bias when 
studies with varying assessment-schedules are used in unanchored comparisons using methods such as matching-
adjusted indirect comparisons.   
Objective 
We illustrate assessment-time bias (ATB) in a simulation study based on data from a recent study in second-line 
treatment for locally advanced or metastatic urothelial carcinoma,and present a method to adjust for differences in 
assessment schedule when comparing progression-free survival against a competing treatment.   
Methods 
A multi-state model for death and progression was used to generate simulated death and progression times from 
which PFS times was derived. PFS data were also generated for a hypothetical comparator treatment by applying a 
constant HR to the baseline treatment. Simulated PFS times for the two treatments were then aligned to different 
assessment schedules so that progression events were only observed at set visit times, and the data were analysed to 
assess the bias and standard error of estimates of hazard ratios between two treatments with and without assessment-
schedule matching (ASM). 
Results 
ATB is highly affected by the rate of the event at first assessment time; in our examples, the bias ranged from 3% to 
11% as the event rate increased.  The proposed method relies on individual-level data from a study and attempts to 
adjust the timing of progression events to the comparator’s schedule by shifting them forward or backward without 
altering the patients’ actual follow-up time.  The method removed the bias almost completely in all scenarios 
without affecting the precision of estimates of comparative effectiveness.   
Conclusions 
Considering the increasing use of unanchored comparative analyses for novel cancer treatments based on single-arm 
studies, the proposed method offers a relatively simple means of improving the accuracy of relative benefits of 
treatments on progression times. 
  
Key Points for Decision Makers 
1. Indirect treatment comparisons based on single-arm studies may be biased by differences in schedules for 
tumour imaging, favouring the treatment with visits scheduled with longer intervals. 
2. The size of the bias is highly affected by the distribution of events over time and becomes larger when 
these occur early, in which case even relatively small differences in schedule (e.g. 2 weeks) may be 
sufficient to bias estimates of relative effect and generate misleading conclusions 
3. Assessment-schedule matching offers a relatively simple and adaptable means of adjusting for this bias and 
should be used prior to conducting unanchored comparisons of treatments in health technology assessments 
such as population-adjusted indirect comparisons. 
 
1. Introduction 
Time-to-event outcomes are often measured on a continuous scale based on the time elapsed between some 
meaningful starting point (e.g., date of randomisation or start of treatment) until the date at which the event of 
interest (e.g., death) occurs.  Some types of events such as response-to-treatment or progression of disease are 
evaluated at scheduled study visits and cannot be measured at the exact time they occur.  The time at which the 
event is recorded is interval-censored, meaning that it must have occurred sometime between the current and last 
visit when the patient was known to be event-free.   
A notable example is progression-free survival (PFS) in studies of cancer treatments.  PFS is a composite endpoint 
defined as the earlier of death or progression of disease, with those patients not experiencing either event treated as 
censored at the end of follow-up.  While exact dates of death are usually known, progressions are mostly identified 
at assessments conducted at pre-determined intervals as per study protocol. Scheduled assessments can vary 
according to the type of treatment, and hence, across different studies. Furthermore, in practice the exact schedule 
may deviate from the planned schedule.    
Interval-censored outcomes are commonly analysed by treating events recorded at assessment times as exact. 
However, the nature of interval-censored outcomes implies that estimates of the risk of the outcome are 
underestimated at times between scheduled visits, as events are recorded with a systematic delay at the following 
visit.  Estimation of progression-free survival can be biased if intermittent assessment of progression is not 
appropriately considered.1  Panageas et al.2 conducted a simulation study demonstrating this bias according to 
various definitions of PFS, but found that comparative analyses between groups following the same assessment 
schedule were not affected.  Any distortions associated with the schedule are common to the groups and likely 
cancel out in estimates of relative effect such as hazard ratios (HRs).  Similar findings were reported by Qi et al. in a 
later study.3   
While these studies would suggest that estimates of relative treatment effect within studies may be robust, the same 
cannot be assumed for comparisons of outcomes with treatments from different studies following different 
schedules.  This may occur, for example, when unanchored indirect treatment comparisons (ITCs) are either based 
on single-arm studies or, in the absence of a common reference arm, on randomized trials.  These ITCs are 
becoming increasingly common in health technology assessments (HTAs), especially for novel cancer treatments 
approved using single-arm trials conducted in high unmet need population.  Between 2009 and 2014, the US Food 
and Drug Administration (FDA) assessed 54 drugs in 64 indications based on single-arm studies.  The European 
Medicine Agency (EMA) assessed 35 drugs in 44 indications over the same period.4  As of November 2017, 
Alexiou et al.5 identified 13 National Institute for Health and Care Excellence (NICE) technology appraisals 
supported by single-arm studies. 
Unanchored ITCs based on single-arm studies are prone to several potential challenges including potential 
confounding bias because of differences in the populations of the studies with respect to treatment effect modifiers 
and prognostic factors of the outcome.6  Methods such as matching-adjusted indirect comparisons (MAIC)7 or 
simulated treatment comparisons (STC)8 can address such imbalances, but cannot address bias arising from different 
assessment schedules used in the studies.  For example, suppose two treatments are studied in single-arm studies 
with identical populations and have identical clinical efficacy (i.e., risk of progression), but in one study disease 
progression is assessed every 4 weeks whereas it is assessed every 9 weeks in the other study.  The treatment in the 
second study will falsely appear to have a lower risk of progression than the treatment in the first study and will lead 
to biased estimates of relative effect. 
We define this phenomenon as assessment-time bias (ATB) and propose a method to reduce the bias in estimates of 
relative effect on PFS in ITCs of single-arm studies with differing assessment schedules.  The described method for 
assessment-schedule matching (ASM) is shown to correct the bias in a simulation study varying some of the key 
parameters affecting the size of bias.  
2. Context of the Problem 
The discussion of ATB and the proposed ASM method will be framed in the context of an unanchored ITC of PFS 
(i.e., when there is a disconnected treatment network or single-arm studies).  It is assumed that individual patient 
data (IPD) are available for one of the studies; we refer to this as the index study and index treatment.  Data for the 
second or comparator study are assumed to only be available from a publication. A MAIC or STC in this context 
would first estimate an adjusted PFS survival function for the index treatment which reflects the expected survival in 
the comparator’s population.  This is then contrasted with the comparator treatment’s PFS survival function to 
estimate a relative effect such as a HR.  We postulate that when the schedule of assessment of disease progression 
differs between two studies, ASM is necessary prior to deriving the estimate of relative effect.  This paper will focus 
specifically on this correction step, as other steps of the comparative analyses would be applied per usual. 
We use a case study based on an immunotherapy study for bladder cancer to illustrate the method.   PFS survival 
functions for these treatments are characterized by a sharp drop at the first assessment time followed by a relatively 
steady decline and, in some cases, an eventual plateau.  It is not uncommon for a significant portion (often more than 
half) of the patients to have experienced disease progression or died prior to the first assessment time.  Assessment 
schedules for studies will determine timing of assessments to capture the median by this point. Figure 1 shows 
representative examples of PFS survival functions estimated in recent immunotherapy studies in advanced urothelial 
and gastric cancer.9-12 In all cases, the survival functions drop below the median at their respective first assessment 
time; assessment time is, therefore, likely to be the most important driver of bias because most of the events 
observed in the study have already occurred.  It may be sufficient for studies to differ only in the first assessment 
time for bias to occur.  A study with a longer assessment interval may also be more likely to miss disease 
progression in patients who drop out of the study early, further slowing the drop in the observed PFS survival 
function. 
3. Assessment-schedule matching (ASM) 
3.1 Overview and Notation 
The proposed method aims to adjust the PFS survival function of the index treatment to reflect what would have 
been observed if the study had followed the comparator’s assessment schedule for progressive disease.  The 
adjustment must be made in this direction because individual patient-level data are only available from the index 
study.  Furthermore, this is consistent with the direction of adjustment in the MAIC or STC for which the correction 
is required.   
A PFS event can occur in one of three ways: a patient dies prior to disease progression being observed; disease 
progression is recorded at an unplanned visit between scheduled study assessments; or disease progression is 
recorded at a scheduled assessment time.  Patients not experiencing one of these three scenarios are censored for 
PFS, typically on the date of their last tumour assessment.  The method only adjusts events recorded at a scheduled 
assessment time.  Death times are known exactly and are unaffected by the studies’ assessment schedules; the same 
can be assumed for disease progression observed at unplanned medical visits because these are prompted by 
aggravation of the patients’ condition.  Thus, the timing and occurrence of these events are not subject to 
adjustment.  
Suppose that assessments are made at times 劇怠┸ 劇態┸ 劇戴┸ ┼ ┸ 劇懲  in the index study, while the comparator study 
scheduled visits are at 劇怠茅┸ 劇態茅┸ 劇戴茅┸ ┼ ┸ 劇暢茅 .  It is possible that assessment times are not perfectly interspersed; that is, 
we may not necessarily have 劇怠 隼 劇怠茅 隼 劇態 隼 劇態茅 隼 劇戴 隼 劇戴茅┸ ┼.  Indeed, studies may only differ in the first few 
visits and subsequently align; for example, theoretically the index study may schedule visits at 4, 8, 12 weeks, and 
every 12 weeks thereafter, and the comparator study conducts assessments at weeks 6, 12 and every 12 weeks 
thereafter.  It is also possible that multiple visits from one study fall in the interval of the other study’s schedule.  For 
instance, we may have 劇怠 隼 劇態 隼 劇怠茅 隼 劇戴 隼 劇態茅, ….  To simplify the discussion, and without loss of generality, we 
assume that in these cases, events from the multiple visits falling between visits scheduled in the comparator study 
can be pooled and processed together, so that we can conceptualise these as a single visit.  In what follows we 
assume that at most one index visit happens between comparator visits, and that the comparator study follows a 
longer interval at least at the first assessment i.e., 劇怠 隼 劇怠茅 判 劇態 隼 劇態茅 判 劇戴 隼 劇戴茅┸ ┼ ┸ ┼  We consider how to handle 
cases following a different pattern further below. 
The method proceeds by estimating how many progressions from the index study would be captured at each 劇沈茅 by 
shifting the events captured at visit 劇沈  forward, and an appropriate proportion (喧) of those captured at 劇沈袋怠 backward.  
Additionally, the method ensures that any shifted progression times do not exceed death or censoring times, as these 
progressions would have been missed at 劇沈茅.  For instance, suppose 20 patients have progressed at 劇怠 噺 は weeks, one 
of whom then dropped out of the study at week 7.  If the first assessment had been scheduled at 劇怠茅 噺 ぱ weeks, only 
19 of the 20 progressions would have been captured.  Suppose further that 9 patients had progressed at  劇態 噺 なに 
weeks; some fraction of these would have occurred between 6 and 8 weeks and, therefore, captured at 劇怠茅 噺 ぱ.  A 
simple approximation would be that this fraction is  喧 噺 脹迭茅貸脹迭脹鉄貸脹迭 噺 態滞 噺 ど┻ぬぬ, assuming an even distribution of the 
events in the interval.  This implies that 3 of the 9 events would have been picked up at 劇怠茅, leading to a total of 22 
progressions. 
Figure 2 illustrates the adjustment process; the details of the approach, and more precise means of deriving 喧 are 
described in the following sections  
3.2 ASM Method 
We denote by 酵珍 the PFS time of the 倹痛朕 patient in the index study, and by 貢珍 their status where 1 indicates they 
progressed or died, and 0 indicates they were censored for PFS, i.e., event-free and alive at the end of their follow-
up.  We aim to derive 酵珍茅 and 貢珍茅, the PFS time and status we would have observed if the index study followed the 
assessment schedule of the comparator study. 
As noted above, not all progression events in the index study are subject to adjustment.  Patients who had death as 
the first event recorded or a progression detected at an unplanned visit between scheduled assessments would be 
expected to have these same times recorded under the comparator’s schedule.  Thus, for these patients 酵珍茅 噺 酵珍 and 貢珍茅 噺 貢珍.  The same is assumed for censoring times. This is a conservative approach for the index treatment because 
forward shifting of censoring times would require assuming that the patient was followed longer than observed; 
adjustment by backward shifting would not be applicable because the patient is known to be progression-free up to 
the time of censoring so any evaluation of disease progression before censoring would capture the progression-free 
status of the patient and this would be captured by the proposed algorithm. 
Adjustment is applied only for patients who had disease progression recorded at a scheduled assessment time.  For 
these patients, the progression time will correspond to one of 劇怠┸ 劇態┸ 劇戴┸ ┼ ┸ 劇懲 , but may vary slightly because not all 
visits would fall exactly on schedule to the day.  We denote by 券沈 the number of patients whose disease progression 
was recorded at 劇沈 .  
The adjustment process then iterates through each of the assessment schedules of the comparator study (劇沈茅), and 
shifts progressions from visits immediately preceding and following this time in the index study, where it is assumed 
that 劇怠 隼 劇怠茅 判 劇態 隼 劇態茅 判 劇戴 隼 劇戴茅┸ ┼.   
3.2.1 Adjustment of the First Visit 
We first describe the steps involved in adjusting the progression times and status for patients whose disease 
progression was recorded at 劇怠. 
Step 1. Forward Shift 
The first step involves advancing the times of individual disease progression at 劇怠 in the index study to  劇怠茅, because 
these events would only have been detected at that time.  This is done based on individual progression times to 
preserve the observed variation around visit dates, and only in cases where these occur at least one week earlier than 劇怠茅 (i.e.,  劇怠茅 伐 劇怠珍 伴 なweek) to reflect the fact that studies typically allow a buffer around scheduled assessments.  
Thus, those events already falling within a week of the comparator’s assessment time may have counted as the 
patient’s study visit and not shifted further.  
The adjusted time for these patients is then given by 
酵珍茅 噺  崕劇怠珍 髪 岫劇怠茅 伐 劇怠岻 if   劇怠茅 伐 劇怠珍 伴 な劇怠珍 if   劇怠茅 伐 劇怠珍 判 な 
for 倹 噺 な┸ ┼ ┸ 券怠. 
Step 2. Correction for Death or Censoring 
Death or censoring time, whichever occurs first, and status are denoted 経珍and 絞珍 (1 if the patient dies and 0 if 
censored) and are assumed fixed and not subject to adjustment.  Thus, if 酵珍茅 exceeds 経珍 , it is assumed that the 
progression event would be missed at 劇怠茅.  The adjusted PFS time is then set to 酵珍茅 噺 経珍 , and 貢珍茅 噺 絞珍.  Thus, a patient 
who was censored at 経珍 , would no longer be counted as an event; a patient who had died would count as an event at 
the time of the death rather than the adjusted progression time. 
Step 3. Backward Shift 
The final step of the algorithm involves shifting events from 劇態 back to 劇怠茅, since some of these events would be 
expected to occur between 劇怠 and 劇怠茅.  Three approaches are considered to estimate the proportion of events to be 
shifted backward (喧怠).   
Approach 1: Linear Interpolation 
A simple way to estimate 喧怠is by linear interpolation; that is, assuming events in the period occur uniformly, and 
therefore, the proportion 喧怠 噺 脹迭茅貸脹迭脹鉄貸脹迭 of the events would have been captured at 劇怠茅.   
Approach 2: Progression Probability-Based Calculation 
To capture variation in risk of disease progression in the interval, 喧怠 may be calculated based on the proportional 
change in the survival probabilities at 劇怠, 劇怠茅and 劇態.  That is: 喧怠 噺 聴岫脹迭岻貸聴岫脹迭茅岻聴岫脹迭岻貸聴岫脹鉄岻, 
where 鯨岫糾岻 are probabilities of being progression-free derived from a parametric survival model fitted for time to 
progression (TTP) while accounting for the interval-censored nature of progression times.  
Approach 3: Worst-case Scenario 
Alternatively, 喧怠 can be set to 1 assuming that all 券態 patients would have progressed by 劇怠茅. This is likely an 
unrealistic scenario; however, there is value in exploring this approach as a “worst-case scenario”.  
 
For a given 喧怠, the progression times are shifted back to 劇怠茅 (i.e. 酵珍茅 噺 劇怠茅 ) for 券態茅 噺 ceiling岫喧怠 抜 券態岻 out of the 券態 
patients observed to progress at 劇態, where ceiling岫捲岻 is the smallest integer greater than or equal to 捲. 
Figure 3 illustrates the adjustment steps at the first visit. 
3.2.2 Adjustment of Subsequent Visits 
The process for adjustment of subsequent visits follows the same steps as described above, with one change to step 
1.  Due to the backward shift in step 3, only a portion of the patients progressing at later visits are available to be 
shifted forward.  Thus, for patients progressing at visits 劇沈  for 件 半 に, step 1 would derive adjusted times as follows:  酵珍茅 噺  崕劇沈珍 髪 岫劇沈茅 伐 劇沈岻 if   劇沈珍 伐 劇沈茅 伴 な劇沈珍 if   劇沈珍 伐 劇沈茅 判 な 
where 倹 references the set of 券沈 伐 券沈茅 patients that were not shifted backwards at the previous iteration of the 
algorithm. Steps 2 and 3 would follow as above.   
It is worth noting that in situations where the visits in the studies coincide (i.e., 劇沈茅 噺 劇沈), the steps of the algorithm 
will inherently produce no change in the observed event times as the adjustment 岫劇沈茅 伐 劇沈岻 would equate to 0.  
The adjustment can proceed iteratively up to the latest assessment time between the two studies (i.e., min 岫劇懲 ┸ 劇暢茅 岻).  
If 劇懲 伴  劇暢茅 , an adjustment would not be possible at visit 劇懲 , and the process stops after adjusting  劇懲貸怠;  if, on the 
other hand, 劇懲 隼  劇暢茅 , step 3 cannot be implemented for 劇懲 , and the process stops after step 2. 
3.2.3 Dealing with Other Assessment Patterns 
The discussion so far has assumed 劇怠 隼 劇怠茅 判 劇態 判 劇態茅 判 劇戴 判 劇戴茅┸ ┼.  In practice, any number of patterns, both 
regular and irregular, may be observed.  One specific scenario of interest is when the assessment intervals are longer 
in the index study: 劇怠茅 隼 劇怠 判 劇態茅 判 劇態 判 劇戴茅 判  劇戴 ┼.  Given that adjustment is done based on the index study where 
IPD are available, forward shift is not possible as the first step in the algorithm.  In this scenario, progressions at 劇沈  
must first be shifted backward (step 3) based on the appropriate proportion, 喧沈; the balance of the patients are then 
shifted forward as described in steps 1 and 2.  When the intervals follow an irregular pattern where there is no 
consistent ordering between the index and comparator studies, the algorithm must consider the sequence and apply 
the steps accordingly. 
3.2.4 Adjustment for All vs. Some Visits 
While it is possible to adjust all visits, it is advisable to consider whether this is necessary or even beneficial.  For 
instance, in the context of PFS survival functions that are characterised by a sharp drop at the first assessment time, 
ATB is likely to be driven mostly by the misalignment of visits at that first occasion.  Thus, it may be possible to 
remove potentially ATB completely by applying adjustment at this point.  In addition to simplicity, this has the 
added advantage of minimizing alterations to the index data, particularly the re-censoring of some of the 
progressions in step 2. A third advantage in applying ASM at the first visit only is that reliance on the interval-
censored model in step 3 is minimised as this model may provide less reliable estimates at later times because of 
progressive loss of power particularly when data are immature. A focused adjustment (i.e. on first assessment visit) 
would also be sufficient in cases when the relative schedules have an irregular order where distortions may naturally 
cancel out. 
The assessment of the statistical properties of the approach using simulations considered both the scenario of 
adjusting the first assessment time only as a primary approach and the added value of full adjustment.   
4. Simulation Study 
4.1 Overview 
To illustrate and assess the statistical properties of  the method, we conducted a simulation study based on the PFS 
survival function estimated in a recent study of patients receiving second line treatment for locally advanced or 
metastatic urothelial carcinoma.13  This required first developing a model for PFS based on the study data.  A multi-
state model for death and progression was used and calibrated to capture the early rate of progression (i.e., sharp 
drop in the PFS survival function) accurately.  The model was then used to generate simulated death and progression 
times from which PFS times can be derived under different scenarios, varying parameters like the rate of early 
progression, sample size and duration of follow-up.  PFS data were also generated for a hypothetical comparator 
treatment by applying a constant HR to the baseline treatment.  Simulated PFS times for the two treatments were 
then aligned to different assessment schedules so that events were only observed at set visit times.  The schedules 
used for the two treatment groups were varied in the simulation, as was the approach used to derive the backward 
shift proportion.  Simulated data were analysed to assess the bias and standard error of estimates of HRs between 
treatments with and without ASM.   
4.2 Modelling PFS for Simulation 
In the study used as a basis for the simulation, PFS was measured by radiographic imaging following a six-weekly 
schedule for the first 12 months, and a twelve-weekly schedule thereafter. Figure 4 shows the empirical PFS survival 
function used as a basis to simulate data to test the approach. This follows the expected pattern with nearly half of 
patients having an event by the time of the first scheduled assessment.   
 
A model was needed from which actual PFS times could be simulated on a continuous scale (i.e., independent of 
any scheduled visit times).  A piecewise multi-state model (Figure 5) based on an exponential distribution over 
weeks 0 to 6 (the first assessment time), and a Weibull distribution thereafter was used. This approach was selected 
to enable the differentiation of PFS events into progressive disease and deaths and to facilitate the investigation of 
different scenarios on the magnitude of the initial decline in PFS at 6 weeks. Furthermore, to reflect the PFS at 6 
weeks accurately, the parameter of the exponential distributions was calculated based on the observed survival 
proportions for each of the three outcomes.  The Weibull segments were estimated by maximum likelihood.  This 
model provided a good fit to the data (Figure 4, green curve) and was adopted for the simulation. 
 
PFS times were simulated for individual patients by inverting the survival functions corresponding to each of the 
transitions in the model.  This produced a triplet consisting of a sampled time for progressing prior to death (PD), 
dying prior to progression (TTDBP) and dying after progression (PPS).  To mimic censoring that would occur in 
studies, a maximum follow-up (MFU) duration was assumed, and events occurring after this time were considered 
censored.  This is a simplification of what happens in studies where patients may have variable follow-up duration 
because of staggered enrolment or early drop out, but we do not expect this to affect our analyses because censored 
values are not modified in the method.   
If the sampled PD or TTDBP values did not exceed the maximum follow-up time, the patient was considered to 
have a PFS event with 酵珍 噺 min盤鶏経珍 ┸ 劇劇経稽鶏珍 ┸ 警繋戟匪 and 貢珍 噺 な if event times preceded MFU, and 0 otherwise.  
PPS times were used to calculate overall survival or censoring time: 経珍 噺 min 岫鶏経珍 髪 鶏鶏鯨珍 ┸ 警繋戟岻 and event status 
(絞珍), which are needed in the adjustment process.  PFS times were also simulated for a hypothetical comparator 
study following this process after applying a fixed HR to each of the hazard functions in the model.   
To induce interval-censoring, the index and comparator PFS times were aligned to two different assessment 
schedules.  All progression events were moved to, and the PFS times were reset to the closest assessment time 
following the event (e.g., 6 weeks). No stochasticity was applied to create distortions in individual visits around the 
assessment time. This may underestimate the variability that occurs in actual studies but is not expected to bias our 
analyses in a systematic way. 
The simulation process was replicated to generate 1000 datasets under different scenarios, each containing observed 
and ATB-adjusted PFS times for the index group and observed times for the comparator.  Cox proportional hazards 
models were fitted to obtain estimates of the HR between treatments based on the observed and adjusted times after 
ASM.  These estimates were contrasted with the true value during simulation to quantify the bias.  Mean estimate of 
HRs across replications, percentage bias, 95% confidence interval limits, coverage probabilities (i.e. the proportion 
of replications when the estimated confidence interval contained the true HR), root mean square error (rMSE) and 
mean standard error of log HR were derived.  
4.3 Simulation Parameters and Scenarios 
The parameters varied in the simulation are summarized in  
 
 
 
 
 
 
Table 1. In addition to sample size and HR, PFS at the first assessment were varied to capture different degrees of 
potential bias.  Different assessment schedules were also considered to assess whether the relative difference in 
timing affects performance.  Finally, three different options were considered for derivation of the backward shift 
proportion (喧沈) using the approaches described above.  Numbers in bold apply to the base case scenario simulation 
settings; alternative scenarios were then investigated by varying each parameter one at a time. In all cases, ASM was 
applied only at the first assessment point; full adjustment was assessed in the every 6 vs. 9 weeks and every 6 vs. 8 
weeks scenarios as the difference in schedules in other cases were relatively small. 
5. Findings from Simulation Study 
5.1 Illustration of the Bias 
The presence and potential extent of bias according to varying assessment schedules is shown in Figure 6. 
Specifically, 
Figure 6 shows actual and simulated PFS survival functions under differing assessment schedules and varying the 
observed PFS at the first assessment.  The simulated survival functions are generated from the same underlying 
model, assuming a HR of 1.0.  To illustrate the bias, we recorded the median time observed with each assessment 
schedule,and quantified the overall difference between the survival functions in terms of a hazard ratio.  In the 
absence of bias, the medians would be equal in the two scenarios and the hazard ratio would equal 1.  Results are 
summarized in Table 2 and show that the bias at the median of these curves increases with the proportion of events 
observed prior to the first scheduled visit and is larger when assessments are scheduled later.  For instance, when the 
PFS at the first assessment is 0.4, the median from the comparator schedule was estimated to be almost double of the 
actual value.  Similarly, HRs indicate an overall relative difference of 11% between the survival functions when 
40% were progression-free at the first schedule, and 3% when PFS was 80% at the first visit. 
5.2 Results from Simulated Scenarios 
Results of all scenarios investigated are presented in Table 3.  In the base case scenario where the true effect was a 
HR of 1.25, a crude comparison of the index and comparator PFS times led to HRs that were consistently 
underestimated by 8%, on average.  Figure 7 shows the empirical distribution of the estimated HRs in replications of 
the base case scenario with and without ASM.  Crude analyses tended to underestimate the true HR.  The size of the 
bias was generally consistent when sample size, HR, duration of follow-up and assessment schedule were varied, but 
was directly dependent on rate of progression before the first assessment.  The bias was -11.3% on average when 
around 40% were event-free at the first visit, and almost negligible (-2.3%) when around 80% were event-free.  
Coverage probabilities of the 95% confidence interval were consistently below the nominal values, except in the 
case where the event-free rate was high. 
ASM at the first visit almost completely removed the bias observed in the crude analyses across all scenarios.  While 
very small (generally between 0.1% and 0.6% when varying input parameters), the direction of the bias remained 
generally positive.  This may be explained by the upward rounding of the ceiling function in step 3 of the algorithm.  
The adjustment was also effective with the linear interpolation (with a bias of -1.0% on average) and worst-case 
scenario (with a bias of -1.9% on average) approaches to calculating the backward shift proportion, but these were 
not as effective as those using the probability-based calculations.  Coverage probabilities were also restored 
following ASM, and in one scenario (when sample sizes were 250), the adjustment led to a confidence interval that 
excluded the null, identifying an effect that would have been missed in the crude analysis. The rMSE was reduced 
slightly after ASM, driven mostly by the removal of bias in the estimates.  The SE of the effect estimates were not 
affected.  
The base case considered schedules that eventually overlap perfectly.  When considering schedules that differ more 
frequently (e.g., every 6 vs 8, or every 6 vs. 9 weeks), ASM at the first visit was sufficient to remove almost all the 
bias observed in crude comparisons.  This was particularly so with a 3-week difference in schedules where the bias 
was only 0.1% on average.   In sensitivity analyses applying correction at all visits, bias remained negligible (<1%) 
but was found to increase, reflecting that correction at all visits does not produce further improvement in accuracy.  
 
6. Discussion 
Indirect treatment comparisons based on single-arm studies may be biased by differences in outcome assessment 
times, favouring the treatment with visits scheduled with longer intervals.  We showed that the size of the bias is 
highly affected by the distribution of events over time and is particularly important when these occur early – at the 
first assessment in our example.  In these cases, even relatively small differences in schedule (2 weeks in our 
example) may be sufficient to bias estimates of relative effect and generate potentially misleading conclusions.  The 
proposed ASM method reduced the bias almost completely across all scenarios we assessed.  Given that most events 
in our assessments occurred prior to the first assessment time, adjustment at this point was sufficient and further 
gains were not observed by adjusting later visits.  However, this may not be the case in all situations.   
Our example focused specifically on the context of PFS assessment in studies where a large proportion of events 
occur prior to the first visit.  This is common across different cancer types and treatments (Figure 1), and evidence 
suggests that the problem might be more pronounced in studies of immunotherapies because some patients may 
experience hyper-progression causing a sharper drop in estimated survival function.14  In other applications, or in 
cases of less aggressive disease, the early drop in the survival function may be less pronounced or potentially spread 
over the first few assessments rather than only at the first assessment.  The potential for bias may be minimal in 
cases where the survival functions decline steadily.  Given that our simulations did not explore such patterns 
directly, we cannot affirm that adjustment of the first visit is sufficient in all cases.  It is, however, advisable to 
consider ASM beyond the first visit at least in a sensitivity analysis to confirm that the results are robust.  While 
adjusting all visits may be the strictest approach, it requires more manipulation of the original index data, and 
potential censoring of some observed progressions in step 2 of the algorithm.  Furthermore, probabilities used in step 
3 would have to be read from the tail of the modelled TTP curve and may not be as reliable as those from earlier 
portions because of immaturity of data or poor fit of the interval censored model in the tail of the survival function.  
The proposed ASM method assumes death and disease progression detected at unplanned visits (while not common 
in a clinical trial setting) should not be adjusted because these are unlikely to be affected by the visit schedule; 
furthermore, adjustment of censoring times should not be made to avoid making unverifiable assumptions that could 
favour the index study (e.g., extending the patients observed duration of follow-up and treating them as progression-
free during this period). The method only adjusts progression events that are captured at scheduled assessment visits.  
The method further assumes that these events would have been only captured at the next scheduled time of the 
comparator study.  It is possible that some of these progression events would have been captured at unplanned visits 
prior to the comparator’s next scheduled visit and captured earlier.  However, incorporating adjustments for such 
unlikely events would add further complexity, with potentially minimal gain in bias reduction considering the results 
of our simulation.  It should also be acknowledged that the proposed method does not revise times-to-event for 
patients who might have progressed between their last progression assessment and death if their last assessment 
were to take place later within that interval. Although this may favour the index treatment because the time-to-event 
in the original data is overestimated, the same limitation applies to an analysis without ASM.    
Another assumption in the method is that the estimates of the proportion of events to shift backward in step 3 are 
accurate.  These are based on a parametric model fitted to the observed progression times while accounting for 
interval-censoring.  Their accuracy depends on the goodness-of-fit of the chosen model.  In our simulations, the bias 
correction with this approach was only slightly better than corrections based on linear interpolation, which assume 
that events occur evenly in the interval and allocates these proportional to time between visits.  Thus, the method 
may be relatively insensitive to misspecification of the progression models, and the added complexity of using 
probability-based adjustment factors, while more robust, may not always be warranted. 
A few simplifications were made in the simulation process.  Studies were assumed to have similar duration of 
follow-up and censoring only occurred at end of study (and hence, no possibility of informative censoring due to 
selective drop-out affecting results). Furthermore, no unplanned visits were created, and duration of follow-up was 
capped based on an assumed maximum study duration.  Given that the method does not alter these aspects of the 
data, these simplifications are likely to be inconsequential.  Backward shift proportions were also derived once and 
applied across replications to minimize run-time of the analyses.  It is possible that incorporating uncertainty in 
these proportions across simulations would induce more variability in results across replications, but we expect this 
to occur in a random way rather than affecting the direction of bias of the estimates. The simulation process assumed 
that hazards between treatment arms are proportional. Although the proposed method for ASM does not rely on this 
assumption, its properties have not been investigated in the setting where the assumption of proportional hazards is 
violated, and other measures of effect are used for the comparison (e.g., an acceleration or shrinkage factor in an 
accelerated failure time model, differences in means or medians, etc.). 
It is important to note that ASM only corrects for the scheduling between studies being compared.  Indirect 
treatment comparisons of these would have to further consider adjustment for prognostic factors and treatment effect 
modifiers using methods such as MAIC or STC.  It is also important to consider that PFS times remain interval-
censored after adjustment.  These approaches can be applied following their usual steps after applying ASM to the 
index study. 
While the problem of progression times being interval-censored is understood, there are few options to adjust for 
these analytically.  Tanase et al. 15 proposed an exploratory analysis to re-analyse PFS by shifting progression 
assessment schedule. However, we were not able to compare our method to theirs because they did not provide 
sufficient information about their approach and underlying assumptions.  Other strategies may be possible, such as 
those proposed by Panageas et al.2 and Heller et al.16, to deal with interval-censoring of PFS.  While appealing, these 
methods require patient-level data from both studies being compared, which is typically not possible in the context 
addressed here.   
Although the paper has focused on applications in cancer studies and PFS specifically, the method can be adapted to 
any situation where events are assessed on a discrete schedule.  The focus on PFS is relevant and important given 
the clinical landscape with increasingly more treatments being subjected to review while still at early phases of 
development, particularly with novel treatments such as immunotherapies.  When evidence comes from single-arm 
studies or disconnected networks, decisions about the use of such treatments must rely on comparative effectiveness 
analyses using methods for unanchored ITC such as MAIC or STC.  Waiting for evidence from randomized 
controlled trials and anchored comparisons (e.g. network meta-analysis) may not be possible because of ethical 
considerations.  In addition to the commonly known challenges associated with unanchored comparisons (e.g., 
residual confounding), our paper shows that ATB may be another important and substantial source of distortion of 
results that should be considered when performing such comparisons.   
7. Conclusion 
In summary, the proposed method to correct for ATB offers a relatively simple and adaptable means of adjusting for 
these distortions in unanchored comparisons of treatments that may be important when conducting a health 
technology assessment.  
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Table 1. Parameters that were varied in simulations 
Varying parameter Parameter values 
Sample size  75, 100, 250 
HR (comparator vs index treatment) 0.80 (better PFS for comparator), 
1 (no treatment effect), 
1.25 (worse PFS for comparator) 
PFS at 劇怠 0.4, 0.6, 0.8 
Maximum follow-up (weeks) 52, 104, 156 
Progression assessment schedules Index study Comparator study 
6, 12 and every 4 weeks afterwards 8, 16 and every 4 weeks afterwards 
Every 6 weeks Every 8 weeks 
Every 6 weeks Every 9 weeks 
Backward shift proportion calculation Progression Probability, Linear approximation, worst-case 
PFS: progression-free survival, 劇怠: First progression assessment time in index study. Parameters used in the base case scenario are emphasised 
in bold.
 
 
Table 2.  Summary of bias when different assessment schedules are imposed on the same underlying PFS curves. 
 Progression-free survival at 6 weeks 
 40%  60%  80%  
  Estimate (95% 
CI) 
Difference Estimate (95% 
CI) 
Difference Estimate (95% CI) Difference 
Median PFS 
True time to event 
records 
4.2 (3.0, 5.3) - 7.5 (4.2, 10.9) - 18.3 (9.6, 27.0) - 
Simulated PFS with visits 
at 6, 12 and every 4 
weeks afterwards 
6.0 (5.8, 6.2) +43% 10.3 (5.6, 14.9) +37% 
19.6 (10.7, 28.5) 
 
+7% 
Simulated PFS with visits 
at 8, 16 and every 4 
weeks afterwards 
8.0 (8.0,8.0) +90% 9.2 (4.5-14.0) +23% 19.9 (11.7, 28.1) +9% 
Hazard Ratio between Simulated Curves 
HR for PFS with 6, 12, 
16… vs. PFS with 8, 16, 
20, …  
0.89 (0.83-0.95) -11.2% 0.92 (0.87-0.97) -8.0% 0.97 (0.95-1.00) -2.6% 
PFS: progression-free survival, HR: hazard ratio, CI: confidence interval, Diff: difference in medians. 
Table 3. Summary of results on HR with and without ASM 
  
Without ASM With ASM 
Parameter Scenario HR* 95% CI 
% 
Bias 
Cov rMSE 
SE log 
HR 
HR* 95% CI 
% 
Bias 
Cov rMSE 
SE log 
HR 
Base case 
True HR*=1.25 1.15 (0.86, 1.54) -8.2% 91.3% 0.196 0.150 1.26 
(0.94, 
1.67) 
0.6% 96.1% 0.187 0.149 
Sample size 75 1.15 (0.82, 1.61) -8.4% 92.5% 0.220 0.174 1.26 (0.90, 
1.75) 
0.4% 95.2% 0.218 0.173 
250 1.14 (0.95, 1.37) -8.6% 83.9% 0.148 0.095 1.25 
(1.05, 
1.50) 
0.4% 95.5% 0.116 0.094 
PFS at 参層 0.4 1.11 (0.83, 1.48) -11.3% 87.2% 0.209 0.148 1.26 (0.95, 
1.66) 
0.6% 96.3% 0.181 0.147 
0.8 1.22 (0.90, 1.65) -2.3% 94.9% 0.190 0.154 1.25 
(0.93, 
1.69) 
0.3% 96.4% 0.193 0.153 
Follow-up 52 weeks 1.14 (0.84, 1.55) -8.8% 90.4% 0.207 0.157 1.26 (0.93, 
1.70) 
0.6% 95.4% 0.198 0.156 
156 weeks 1.15 (0.86, 1.54) -7.9% 91.0% 0.192 0.148 1.26 
(0.95, 
1.67) 
0.6% 95.8% 0.185 0.147 
Progression 
assessment 
schedules + 
Adjusting First 
Visit 
Every 6  
vs 8 weeks 
1.15 (0.86, 1.54) -8.0% 91.4% 0.195 0.150 1.26 
(0.95, 
1.68) 
0.8% 96.2% 0.188 0.150 
Every 6  
vs 9 weeks 
1.14 (0.85, 1.53) -8.9% 90.5% 0.199 0.150 1.25 
(0.94, 
1.67) 
0.1% 95.9% 0.186 0.150 
Progression 
assessment schedules 
+ Adjusting All Visits 
Every 6  
vs every 8 weeks 
 1.26 
(0.95, 
1.68) 
0.9% 96.1% 0.188 0.149 
Every 6  
vs every 9 weeks 
 1.26 
(0.95, 
1.68) 
0.8% 95.7% 0.188 0.150 
ATB correction 
scenario 
Worst-case 
Scenario 
 1.23 
(0.92, 
1.63) 
-1.9% 95.2% 0.182 0.150 
Linear 
Interpolation 
 1.26 
(0.95, 
1.68) 
1.0% 96.0% 0.189 0.149 
HR  
(comp vs index) 0.80 0.74 (0.55, 1.01) -7.2% 92.4% 0.127 0.154 0.80 
(0.59, 
1.09) 
0.1% 94.5% 0.126 0.154 
  
Without ASM With ASM 
Parameter Scenario HR* 95% CI 
% 
Bias 
Cov rMSE 
SE log 
HR 
HR* 95% CI 
% 
Bias 
Cov rMSE 
SE log 
HR 
1 0.92 (0.69, 1.24) -7.6% 91.8% 0.157 0.151 1.00 
(0.75, 
1.35) 
0.5% 95.4% 0.153 0.151 
ASM: assessment-time matching, PFS, progression-free survival; HR, hazard ratio; CI, confidence interval, Cov, coverage; rMSE, root mean square error; SE, standard error; 劇怠: first progression 
assessment time in index study.  
The base case scenario used a sample size of 100 patients in each study, HR=1.25, maximum follow-up 104 weeks, progression assessments at 6, 12 and every 4 
weeks afterwards for index study and at 8, 16 and every 4 weeks afterwards for comparator study, and backward shift proportion calculation based on 
progression probability approach. Alternative scenarios were investigated by varying each parameter one at a time. 
 
Figure Legend 
Figure 1. Progression-free survival in immunotherapy studies in aggressive carcinomas 
Figure 2. Diagram Illustrating the ASM Approach 
Figure 3. Description of adjustment steps at the first assessment points. 
Figure 4. Empirical Progression-Free Survival Curve used as the basis for the Simulation Study. 
Figure 5. Structure of the three-state model for PFS fitted to the study data and used in simulations. 
Figure 6. ATB on median PFS under different progression rates at the first assessment point. 
Figure 7. Empirical density of HRs across 1000 replications of the base case scenario
Figure 1. Progression-free survival in immunotherapy studies in aggressive carcinomas 
Advanced urothelial carcinoma   
  
Advanced gastric cancer 
  
PFS: progression-free survival. Times shown reflect the schedule of progression assessment in each study. The red vertical line corresponds to 
the first schedule of progression assessment. 
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Figure 2. Diagram Illustrating the ASM Approach for matching the first progression assessment time 
 
 劇怠: First progression assessment time in index study, 劇態: Second progression assessment time in index study, 劇怠茅: First progression assessment 
time in comparator study, 劇態茅: Second progression assessment time in comparator study, 喧: proportion of patients for whom progression could 
have been captured if the index study had an assessment scheduled at 劇態茅. Dots have been spread out vertically for illustration purposes to 
avoid overlap; the vertical distance of the dots from the horizontal axis is not informative. Blue dots represent progression times recorded at 
unplanned visits or death times (not altered by the ASM method). White dots represent censored times (not altered by the ASM method). 
Yellow dots represent the progression times shifted forward by 劇怠茅 伐 劇怠 in step 1 of the ASM method. Purple dots represent the progression 
times that were shifted forward in step 1 of the ASM algorithm but were corrected for death or censoring in step 2 of the ASM method. Green 
dots represent progression times shifted backwards in step 3 of the ASM method. Grey dots represent progression times at 劇態 that were not 
shifted backwards in step 3 of the ASM method.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Description of adjustment steps at the first assessment points. 
 
TTE: time to event, PD: progressive disease, 劇怠珍: First progression assessment time for patient 倹 in index study, 劇態珍: Second progression 
assessment time for patient 倹 in index study, 劇怠: First progression assessment time in index study, 劇怠茅: First progression assessment time in 
comparator study, 経珍: death or censoring time for patient 倹 in the index study.  
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record 
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radiologic PD (no death event, censoring or 
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Do not 
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Figure 4. Empirical Progression-Free Survival Curve used as the basis for the Simulation Study. 
 
Dashed lines represent 95% confidence band around the observed PFS curve. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Structure of the three-state model for PFS fitted to the study data and used in simulations. 
 
PF = Progression free; PD = Progressed disease; D = death; h(t) = hazard of transitioning from one node to the other; TTP = Time to progression; 
PPS = Post-progression survival; TTDBP = Time to death before progression. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. ATB on median PFS under different progression rates at the first assessment point. 
 
ATB: assessment-time bias, PFS: progression-free survival. 
Figure 7. Empirical density of HRs across 1000 replications of the base case scenario. 
   
HR: hazard ratio, ASM: assessment-schedule matching 
 
 
 
